2020 Pharmaceutical manufacturing Specialization 
pharmaphorum
DECEMBER 16, 2022
The world was caught unprepared for the global pandemic that struck in 2020. The UN Special Rapporteur on contemporary forms of racism, E. Further, with a pandemic treaty in development, there are reasons to believe that many countries and the WHO want to see a more equitable distribution of medical products for future pandemics.
European Pharmaceutical Review
DECEMBER 21, 2022
2 However, most of these efforts relating to catalysis, 3 process waste metrics, 4 lifecycle assessments, 5 pharmaceuticals in the environment 6 and the phase out of substances of concern 7 mainly mitigate the consequences of pharmaceutical manufacturing. Gene Ther 27, 537–544 (2020). Science 369, eabc3183 (2020).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
JULY 8, 2024
2,3 Mono-temperature incubation will also receive special attention when A3P Association’s Microbiology common interest group (CIG) members carry out specific work. In the absence of any regulatory text, numerous presentations have been made on the subject, prompting debate and initiating reflection.
pharmaphorum
OCTOBER 26, 2022
Founded in 1935 by Chiesi’s grandfather of the same name, Chiesi Group focuses on respiratory conditions, special care, and on rare diseases, including lysosomal storage disorders and rare haematological and ophthalmological diseases. “An About the author. For further information please visit www.chiesi.com. About Chiesi Global Rare Diseases.
PM360
AUGUST 26, 2024
During the period from 2008 through 2020, the number of precision medicines in the US increased from 5 to 285. When once a small population needed a special status called “rare”, now all diseases will be defined by endotypes and phenotypes – smaller segments of like patients with common molecular characteristics.
Expert insights. Personalized for you.
96 
Let's personalize your content